Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ashby

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Blood|July 29, 2025
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AMLRithin Nedumannil, Michael Ashby, James P Rowland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
British Journal of Haematology|January 10, 2024
Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemiaZoe Loh, Michael Ashby, Ellie Van Veldhuizen, et al.
Transplantation and Cellular Therapy|June 6, 2026
Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell TransplantationNermen Tawfik, Ashleigh P Scott, Catelyn Cashion, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Blood|July 29, 2025
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AMLRithin Nedumannil, Michael Ashby, James P Rowland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
British Journal of Haematology|January 10, 2024
Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemiaZoe Loh, Michael Ashby, Ellie Van Veldhuizen, et al.
Transplantation and Cellular Therapy|June 6, 2026
Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell TransplantationNermen Tawfik, Ashleigh P Scott, Catelyn Cashion, et al.
Pageof 5